-
Mashup Score: 3
Results from INVIGORATE-2 showed IV secukinumab led to improved clinical measures of PsA, with a similar safety profile to subcutaneous secukinumab.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3
Results from INVIGORATE-2 showed IV secukinumab led to improved clinical measures of PsA, with a similar safety profile to subcutaneous secukinumab.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3
Results from INVIGORATE-2 showed IV secukinumab led to improved clinical measures of PsA, with a similar safety profile to subcutaneous secukinumab.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Blue-collar workers with psoriatic arthritis demonstrate an increased risk for work disability vs. white-collar workers with the same disease, according to data published in Clinical Rheumatology.However, the researchers additionally concluded that occupation type does not appear to impact response to PsA treatment.
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0Ejim Mark, MD, MPH: Zasocitinib Shows Promise as Next-Generation TYK2 Inhibitor for PsA - 3 month(s) ago
If approved, zasocitinib could become a leading oral treatment for PsA.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Ejim Mark, MD, MPH: Zasocitinib Shows Promise as Next-Generation TYK2 Inhibitor for PsA - 3 month(s) ago
If approved, zasocitinib could become a leading oral treatment for PsA.
Source: www.hcplive.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1
Adults with active PsA treated with guselkumab exhibited durable achievement of study endpoints associated with disease control, irrespective of baseline characteristics.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Biological Agents More Effective Than Methotrexate in PsA Prevention - 4 month(s) ago
Researchers evaluated the impact of different treatment modalities in the prevention of psoriatic arthritis (PsA).
Source: www.ajmc.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Upadacitinib Available for Pediatric Patients with pJIA, PsA - 5 month(s) ago
Upadacitinib is now available as a tablet or an oral solution for patients 2 years and older with pJIA as well as PsA.
Source: www.dermatologytimes.comCategories: General Medicine News, DermatologyTweet
-
Mashup Score: 2
Patients with psoriatic arthritis demonstrated similar disease activity outcomes and drug persistence after long-term treatment with either etanercept or its biosimilar SB4, according to data published in Arthritis Care & Research.“Real-world data focusing on SB4 in PsA is very limited,” Katarzyna osiska, MD, of the division of rheumatology and immunology at University Hospital,
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
Results from INVIGORATE-2 show the benefit of IV secukinumab for the rapid improvement of disease signs and symptoms in patients with active PsA. Find out more: https://t.co/LLV2cFcgoy #PsoriaticArthritis